Live
- Tata Motors’ net profit drops 11 pc on slow JLR, commercial vehicles sales
- In peak poll time, MVA allies target BJP-MahaYuti over 'washing machine politics' in Maharashtra
- PM Modi in Maha rally dares MVA leaders to make Congress praise Savarkar, Bal Thackeray's ideology
- Lee Carsley reveals no contact yet with incoming England Boss Thomas Tuchel
- Satyasai Vratams with Devotion
- Ashok Leyland registers 37 pc jump in Q2 net profit, declares dividend
- Vote for Mahayuti means people are with PM, says HM Shah in Maharashtra
- Neeraj Chopra to commence one month off-season training in South Africa later this month
- Grand Celebrations of CM Revanth Reddy’s Birthday
- Telangana Government Forms Cabinet Sub-Committee to Address Employee Issues
GSK, Pfizer get nod for consumer healthcare JV
The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
New Delhi: The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around $12.7 billion (around
Rs 88,900 crore).
In a tweet, the Competition Commission of India (CCI) said it "approves formation of a JV for consumer healthcare products by GSK and Pfizer."
The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK, as per a notice submitted to CCI.
